| 摘要 |
The present invention provides compounds of Formula I
or pharmaceutically acceptable salt forms thereof, wherein R a , R b , R c , R d , D, W, R 1a , R 1b , R 1c , Y, R 3 , X, E and G are as defined herein, and uses as AXL and c-MET kinase inhibitors . |
